文献速递肿瘤 PET/CT神经核医学

基因分层嗜铬细胞瘤/副神经节瘤队列中[18F]FDOPA摄取的基因型依赖定量证据

Genotype-dependent [18F]FDOPA uptake: quantitative evidence from a genetically stratified PPGL cohort.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-26

该研究纳入69例初诊时行[18F]FDOPA PET/CT且有胚系和/或体细胞检测信息的连续PPGL患者(86个肿瘤病灶),按遗传簇分组进行定量分析。患者基于灵敏度97.1%(67/69;95%CI 89.9-99.7),病灶基于灵敏度94.2%(81/86;95%CI 87.0-98.1%)。2簇肿瘤摄取强度低于散发性、1a簇和1b簇(TBR/SUVmean/SUVmax,p=0.003-0.025),CT肿瘤直径组间无差异(p=0.086-0.927)。

要点

  • 非转移性PPGL病灶基于灵敏度96.3%(77/80;95%CI 89.4-99.2%),转移性为66.7%(4/6;95%CI 22.3-95.7%)。
  • 中位TBR为6.9,显示[18F]FDOPA PET/CT在高对比度成像中的价值。
  • 2簇肿瘤摄取强度低于散发性、1a簇和1b簇(p=0.003-0.025),CT形态学无法区分亚型。

核心结论

  • [18F]FDOPA PET/CT在非转移性PPGL中提供优异的图像对比度,并能区分不同遗传簇,而形态学成像无法实现亚型区分。

研究设计与样本

  • 纳入初诊时行[18F]FDOPA PET/CT且有胚系和/或体细胞检测信息的连续PPGL患者,按遗传簇分组进行定量分析。
  • 共分析69例患者、86个肿瘤病灶,PET定量包括MTV、SUVmax、SUVmean和TBR(SUVmax/肝脏SUVmean),CT测定原发灶直径。
  • 诊断灵敏度通过视觉评估和TBR阈值>2评估,计算病灶基于和患者基于灵敏度,亚组比较采用非参数检验并进行多重性控制。

主要发现

  • 患者基于灵敏度97.1%(67/69;95%CI 89.9-99.7),病灶基于灵敏度94.2%(81/86;95%CI 87.0-98.1%)。
  • 非转移性疾病病灶基于灵敏度96.3%(77/80;95%CI 89.4-99.2%),转移性疾病为66.7%(4/6;95%CI 22.3-95.7%)。
  • 定量分析显示高图像对比度(中位TBR:6.9)。
  • 2簇肿瘤摄取强度(TBR/SUVmean/SUVmax)低于散发性、1a簇和1b簇肿瘤(p=0.003-0.025)。
  • 1b簇和散发性病例的MTV大于2簇(p=0.011-0.018),而CT肿瘤直径组间无差异(p=0.086-0.927)。

关键数值与推荐

  • 诊断灵敏度采用视觉评估和TBR阈值>2进行评估。
  • 遗传簇分组基于胚系和/或体细胞检测信息,分为1a簇、1b簇、2簇和散发性肿瘤。

临床怎么用

  • [18F]FDOPA PET/CT可用于非转移性PPGL的高对比度成像和遗传簇鉴别,辅助亚型分层。
  • 定量参数(TBR、SUVmean、SUVmax、MTV)有助于区分遗传簇,CT形态学参数无此能力。

局限性

  • 转移性疾病病灶基于灵敏度样本量小(4/6),置信区间宽(95%CI 22.3-95.7%)。
  • 单中心连续队列,需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: [18F]FDOPA PET/CT is widely used in the diagnostic work-up of pheochromocytoma and paraganglioma (PPGL), with the latter entity classified into genetic clusters 1a, 1b, and 2 and sporadic tumours, reflecting varying aggressiveness. We aimed to assess diagnostic performance and quantitative [18F]FDOPA uptake across genetic clusters. METHODS: Consecutive PPGL patients with [18F]FDOPA PET/CT at initial diagnosis and available information on germline and/or somatic testing were included. Patients were grouped into genetic clusters. PET quantification included metabolic tumour volume (MTV) and maximum SUV(SUVmax), mean SUV(SUVmean) and tumour-to-background ratio (TBR, SUVmax/liver SUVmean). The diameter of the primary was determined on CT. The diagnostic sensitivity for detecting PPGL lesions was assessed visually and with a TBR threshold > 2. Lesion- and patient-based sensitivities were calculated. Subgroups were compared using non-parametric tests with multiplicity control. RESULTS: 69 patients presenting with 86 tumour lesions were analyzed. Patient-based sensitivity was 97.1% (67/69; 95%-CI 89.9-99.7) and lesion-based sensitivity 94.2% (81/86; 95%-CI 87.0-98.1%). Lesion-based sensitivity was 96.3% in non-metastatic disease (77/80; 95%-CI 89.4-99.2%) and 66.7% in metastatic disease [4/6; 95%-CI 22.3-95.7%]). Quantitative analysis showed a high image contrast (median TBR: 6.9). Cluster 2 showed less uptake intensity than sporadic, cluster 1a and cluster 1b tumours (TBR/SUVmean/SUVmax, p = 0.003-0.025). MTV was larger in cluster 1b and sporadic cases than in cluster 2 (p = 0.011-0.018), whereas tumour diameter on CT did not differ between groups (p = 0.086-0.927). CONCLUSION: [18F]FDOPA PET/CT provides excellent image contrast in non-metastasized PPGL and can differentiate between varying genetic clusters, while morphological imaging failed for subtype segregation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Dahlmann P, Geuss M, Auer M, et al. Genotype-dependent [18F]FDOPA uptake: quantitative evidence from a genetically stratified PPGL cohort. Eur J Nucl Med Mol Imaging. 2026. PMID: 42350615. doi:10.1007/s00259-026-08002-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。